Currently, tumor tissue-based screening for PD-L1 expression is an FDA approved molecular biomarker utilised in tumor types such as non-small cell lung cancers (NSCLC) or melanoma, where IO is being considered predominantly [8,9,10]. The gene discussed is CD274; the disease is neoplasm.